Viatris, Inc. (VTRS)

16.42 +0.08 (+0.49%) USD  |  NASDAQ  |  Aug 31, 14:32
More

Viatris Total Long Term Debt (Quarterly) : 13.51B for June 30, 2026

Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for VTRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 13.51B
March 31, 2026 14.51B
December 31, 2025 14.59B
September 30, 2025 14.61B
June 30, 2025 14.65B
March 31, 2025 14.36B
December 31, 2024 14.23B
September 30, 2024 15.94B
June 30, 2024 17.29B
March 31, 2024 18.13B
December 31, 2023 18.30B
September 30, 2023 18.54B
June 30, 2023 18.75B
March 31, 2023 18.75B
December 31, 2022 19.46B
September 30, 2022 19.67B
June 30, 2022 20.17B
March 31, 2022 21.56B
December 31, 2021 21.80B
September 30, 2021 21.98B
June 30, 2021 23.31B
March 31, 2021 24.62B
December 31, 2020 24.97B
September 30, 2020 12.50B
June 30, 2020 12.35B
Date Value
March 31, 2020 12.85B
December 31, 2019 12.85B
September 30, 2019 13.25B
June 30, 2019 13.49B
March 31, 2019 13.94B
December 31, 2018 13.86B
September 30, 2018 14.47B
June 30, 2018 14.52B
March 31, 2018 14.78B
December 31, 2017 14.67B
September 30, 2017 14.72B
June 30, 2017 14.98B
March 31, 2017 15.00B
December 31, 2016 15.49B
September 30, 2016 15.61B
June 30, 2016 13.27B
March 31, 2016 7.326B
December 31, 2015 7.294B
September 30, 2015 6.348B
June 30, 2015 7.990B
March 31, 2015 8.293B
December 31, 2014 8.138B
September 30, 2014 7.716B
June 30, 2014 7.976B
March 31, 2014 7.834B

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Pfizer Inc. 63.10B
Eli Lilly & Co. 49.62B
Merck & Co., Inc. 51.08B
Bristol Myers Squibb Co. 44.59B
Johnson & Johnson 37.34B